Review anchor
cGMP-dependent 3',5'-cyclic phosphodiesterase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
cGMP-dependent 3',5'-cyclic phosphodiesterase
CHEMBL2652
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats cGMP-dependent 3',5'-cyclic phosphodiesterase as ChEMBL target CHEMBL2652, mapped to UniProt O00408. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2652
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O00408
cGMP-dependent 3',5'-cyclic phosphodiesterase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why cGMP-dependent 3',5'-cyclic phosphodiesterase matters
cGMP-dependent 3',5'-cyclic phosphodiesterase is reviewed as cGMP-dependent 3',5'-cyclic phosphodiesterase (UniProt O00408); the current evidence base includes 5 approved drugs, 3368 compounds, and 318 assays, with lead potency reaching pChEMBL 10.8.
Protein context
cGMP-dependent 3',5'-cyclic phosphodiesterase
cGMP-dependent 3',5'-cyclic phosphodiesterase Sequence length is 941 aa.
Review this target as cGMP-dependent 3',5'-cyclic phosphodiesterase, mapped to UniProt O00408. Sequence length is 941 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O00408
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 3368 compounds, and 318 assays for this target. The dominant activity type is IC50. CHEMBL5827044 is the current potency anchor at pChEMBL 10.8.
Use CHEMBL5827044 as the tractability anchor when discussing potency (pChEMBL 10.8).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 10.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why cGMP-dependent 3',5'-cyclic phosphodiesterase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O00408, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3368
Total Compounds
318
Total Assays
5
Approved Drugs
IC50: 2961.0, KI: 1415.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5827044
|
10.8 | Ki | — |
|
|
No preferred name
CHEMBL5773913
|
10.8 | Ki | — |
|
|
No preferred name
CHEMBL6019094
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL5867733
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL6027642
|
10.6 | Ki | — |
Source Header